This randomized clinical trial compares the effects of negative pressure wound therapy vs standard wound management on disability, deep infections, and quality of life in patients with severe open fracture of the lower limb.
This pharmacoepidemiological study uses NHANES data to investigate the prevalence of use by adults of medications with depression or suicidal symptoms as known adverse events and to analyze the associations between use of those drugs and clinical depression.
This randomized clinical trial compares the effects of recombinant human pentraxin 2, a monocyte differentiation inhibitor, vs placebo on changes in percent predicted forced vital capacity after 28 weeks in patients with idiopathic pulmonary fibrosis.
This pharmacoepidemiology study uses Swedish and Norwegian registry data to investigate associations between fluconazole use during pregnancy and subsequent stillbirth and neonatal death.
This 2018 Recommendation Statement from the US Preventive Services Task Force recommends against ECG screening for CVD in asymptomatic adults at low risk (D recommendation) and concludes that evidence is insufficient to assess the benefits and harms of screening in asymptomatic adults at intermediate or high risk (I statement).
This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for cardiovascular disease (CVD) risk with electrocardiography (ECG) summarizes published evidence on the benefits and harms of screening resting or ECG screening to prevent CVD events.
This Viewpoint discusses the possible harms of controversial state-mandated work requirements for Medicaid beneficiaries and proposes safeguards the Centers for Medicare & Medicaid Services might put in place to minimize health risks to patients.
This Viewpoint discusses management reasoning, ways in which it differs from diagnostic reasoning, and areas that require further research.
This Viewpoint explains the role of pharmaceutical benefit managers (PBMs) in the United States drug and health care market, and the potential effects acquisitions of PBMs by health insurers could have on prices and drug availability.
This Viewpoint uses 3 recent legal antitrust cases filed by pharmaceutical companies against each other to identify mechanisms by which companies suppress competition and keep drug prices inflated, and emphasizes the role of antitrust law as a potentially positive means to open markets and increase access to affordable drugs.
In this medical narrative essay, the author recounts how he transforms oversights of patient evidence while making a diagnosis has helped him develop a strategy to use worry to his advantage.
This JAMA Clinical Update reviews CVD risk stratification of patients with peripheral artery disease (PAD) and current standards of practice for use of antiplatelet and anticoagulant therapies.
In this Medical News article, the Framingham Heart Study’s director, Daniel Levy, MD, discusses women’s participation during the study’s 70-year history.
This JAMA Patient Page describes the US Preventive Task Force’s recommendations on screening for cardiovascular disease risk using electrocardiography (ECG).
Create a personal account or sign in to: